预约演示
更新于：2025-11-08
Naproxen Sodium
萘普生钠
更新于：2025-11-08
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C14H14NaO3 |
InChIKeyCNQOEXOJUIMDHW-FVGYRXGTSA-N |
CAS号26159-34-2 |
关联
37
项与 萘普生钠 相关的临床试验CTR20244059
萘普生钠片（275 mg）在健康受试者中的单中心、随机、开放、单次给药、两序列、两周期、双交叉、空腹及餐后状态下的生物等效性研究
NCT05900336
Non-Steroidal Anti-Inflammatory Drug (NSAID) Response and Central Sensitization of Pain in Women With Dysmenorrhea
CTR20240211
随机、开放、两制剂、两序列、两周期、自身交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服萘普生钠片后的生物等效性正式试验
100 项与 萘普生钠 相关的临床结果
登录后查看更多信息
100 项与 萘普生钠 相关的转化医学
登录后查看更多信息
100 项与 萘普生钠 相关的专利（医药）
登录后查看更多信息
918
项与 萘普生钠 相关的文献（医药）2025-08-01KAOHSIUNG JOURNAL OF MEDICAL SCIENCES
Article
Retraction: R.Polat, K.Peker, Ç. T.Gülöksüz, J.Ergil, T.Akkaya, “,” Kaohsiung Journal of Medical Sciences31, no. (2015): 468–472. https://doi.org/10.1016/j.kjms.2015.07.001.The above article, published online on 06 August 2015, in Wiley Online Library (wileyonlinelibrary.com), and has been retracted by agreement between the journal Editor‐in‐Chief, Wan‐Long Chuang; Kaohsiung Medical University; and John Wiley and Sons Australia, Ltd. In 2021, a third party raised concerns regarding evidence of unlikely similarity in the standard deviation values presented in Figures 1 and 2. The journal contacted the authors, who provided original data for evaluation by the journal. Following further correspondence, the journal and publisher concluded that the authors' response satisfied their concerns and that the investigation should be closed without further action.In 2024, the complainant appealed to the journal and publisher to re‐open the investigation based on the substantial evidence of errors. The publisher accepted this appeal and re‐opened the investigation. The editors have conducted a review of the evidence and the provided dataset and found that the data includes substantial numbers of duplicated values across pairs of patients. The editors have determined that the substantial quantity of duplicated values is incompatible with a genuine randomized controlled trial and that the evidence compromises the conclusions of the article. As such, the parties agree that a retraction is necessary. The authors disagree with the retraction.
2025-08-01TALANTA
Skin-interfaced sweat monitoring patch constructed by flexible microfluidic capillary pump and Cu-MOF sensitized electrochemical sensor
Article
作者: Shi, Huanhuan ; Cao, Yu ; Zhao, Rui ; Zheng, Yun ; Wu, Hongwen ; Tan, Zhongjian ; Jia, Xuanhao ; Xu, Weizheng
The limitations of skin-interfaced sweat monitoring are mainly reflected in the effective collection of sweat and the high sensitivity of the detection. This work proposes a new type of sweat monitoring patch based on a flexible microfluidic chip fabricated by a capillary pump and a copper-based metal-based organic framework (Cu-MOF) sensitized electrochemical sensor. The sweat in the microchannel is driven by a capillary pump to ensure the smooth collection and transportation. The sweat collection channel adopts the ingenious design of wedge-shaped structure, which helps to spontaneously generate Laplacian forces to direct sweat to the detection area. The detection area combines upper and lower capillary pumps, which aim to improve the efficiency of sweat collection. The controllable preparation of Cu-MOF was realized by using a micro-mixer, and the glucose sensor was prepared with it as the probe. The Cu-MOF/PANI layered electrode was prepared, which effectively improved the sensitivity of glucose detection and achieved a significant detection limit of 2.84 μM in the concentration range of 0-1 mM. Sodium and potassium selective electrode were also integrated into a unified screen-printed electrode, and a portable electrochemical detection module, a Bluetooth transmission module, and a mobile phone receiving application were developed. The sweat monitoring patch shows potential in applications such as sports performance monitoring, healthcare, and personalized medicine, opening new avenues for non-invasive health monitoring and early disease detection.
2025-06-01POLYMER ENGINEERING AND SCIENCE
作者: Luo, Hui‐Hong ; Xu, Wen‐Rong
Abstract:
pH‐responsive supramolecular polymeric vesicles were successfully developed through the host–guest complexation of two biocompatible and water‐soluble saccharides: sulfobutylether‐β‐cyclodextrin (SCD) and N‐dodecyl chitosan (DCS). Extensive characterization using UV–vis spectroscopy, dynamic light scattering (DLS), zeta potential measurements, and transmission electron microscopy (TEM) confirmed the structural robustness of the vesicles, which exhibited effective self‐assembly in acidic conditions and disassembly in alkaline environments. To evaluate the drug‐loading capacity and pH‐responsive release properties, naproxen sodium (NS), a widely used nonsteroidal anti‐inflammatory drug, was encapsulated as a model compound. In vitro release studies simulating gastrointestinal pH conditions (2.0, 6.8, and 8.5) demonstrated minimal drug release of (28.34 ± 1.02)% at low pH and significantly enhanced release of (56.57 ± 1.68)% and (86.96 ± 1.29)% at neutral and slightly alkaline pH, respectively. The system exhibited an initial burst release followed by sustained release, aligning with the therapeutic requirements for rapid onset and prolonged action. These findings highlight the potential of SCD/DCS supramolecular vesicles as a versatile platform for targeted oral drug delivery, particularly for drugs requiring intestinal release.
Highlights:
Supramolecular vesicles self‐assembled via sulfobutylether‐β‐cyclodextrin (SCD) and N‐dodecyl chitosan (DCS) host–guest complexation.Vesicles exhibited stability in acidic pH and disassembled in alkaline conditions.Naproxen sodium‐loaded vesicles displayed pH‐sensitive release properties.Drug release occurred in neutral to alkaline pH, ideal for intestinal delivery.
100 项与 萘普生钠 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D00970 | - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性偏头痛 | 澳大利亚 | 1998-11-03 | |
| 强直性脊柱炎 | 美国 | 1980-09-04 | |
| 滑囊炎 | 美国 | 1980-09-04 | |
| 痛风 | 美国 | 1980-09-04 | |
| 幼年特发性关节炎 | 美国 | 1980-09-04 | |
| 骨关节炎 | 美国 | 1980-09-04 | |
| 疼痛 | 美国 | 1980-09-04 | |
| 原发性痛经 | 美国 | 1980-09-04 | |
| 类风湿关节炎 | 美国 | 1980-09-04 | |
| 肌腱病 | 美国 | 1980-09-04 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 290 | placebo (Arm 1: Placebo) | 蓋鬱觸選蓋繭鹹鬱遞膚(夢艱願廠憲廠製觸範襯) = 廠簾遞淵鹽衊選鏇範願 憲鬱夢鬱夢願獵構鑰醖 (鹽繭廠顧壓網膚淵壓醖, 2.181) 更多 | - | 2022-12-05 | ||
(Arm 2: Naproxen Sodium 440 mg) | 蓋鬱觸選蓋繭鹹鬱遞膚(夢艱願廠憲廠製觸範襯) = 餘顧襯艱構築選鑰壓餘 憲鬱夢鬱夢願獵構鑰醖 (鹽繭廠顧壓網膚淵壓醖, 1.562) 更多 | ||||||
临床4期 | 200 | (Naproxen Sodium+Codeine Phosphate) | 選餘壓蓋構範衊獵製構(顧壓鹹範製醖夢壓鹹糧) = 範淵夢範憲鬱繭鏇選繭 積衊鏇鏇範選壓蓋衊構 (繭願繭網膚鏇鬱糧餘醖, 1.86) 更多 | - | 2021-02-15 | ||
(Naproxen Sodium+Dexamethasone) | 選餘壓蓋構範衊獵製構(顧壓鹹範製醖夢壓鹹糧) = 憲蓋廠鏇夢窪廠壓憲窪 積衊鏇鏇範選壓蓋衊構 (繭願繭網膚鏇鬱糧餘醖, 1.76) 更多 | ||||||
临床2期 | 41 | (Naproxen) | 蓋壓夢網壓鹽鬱憲簾膚(選糧衊製鹹蓋簾獵膚鏇) = 醖襯築範觸獵廠憲夢積 衊廠鹹觸醖廠鹽醖鬱蓋 (襯齋顧構憲簾製艱鏇蓋, 5.46) 更多 | - | 2020-06-19 | ||
Acetaminophen (Acetaminophen ER) | 蓋壓夢網壓鹽鬱憲簾膚(選糧衊製鹹蓋簾獵膚鏇) = 鬱遞築獵鹹顧鏇鑰製膚 衊廠鹹觸醖廠鹽醖鬱蓋 (襯齋顧構憲簾製艱鏇蓋, 5.46) 更多 | ||||||
N/A | 119 | (Naproxen Sodium) | 憲願齋築鬱範構衊窪壓(醖膚構鹹積壓淵簾選艱) = 齋構襯襯窪衊簾網觸簾 壓廠遞製醖鹽鏇壓窪憲 (夢鏇鑰淵鏇繭繭遞鹽網, 願範壓顧鬱觸選窪鬱鏇 ~ 選鬱襯範憲觸糧淵鹹獵) 更多 | - | 2017-06-22 | ||
Placebo tablet (Placebo) | 憲願齋築鬱範構衊窪壓(醖膚構鹹積壓淵簾選艱) = 醖構獵襯鏇簾鹹觸鏇願 壓廠遞製醖鹽鏇壓窪憲 (夢鏇鑰淵鏇繭繭遞鹽網, 鹽網鑰簾糧鬱觸餘積鑰 ~ 繭膚鏇選窪願鬱範醖醖) 更多 | ||||||
N/A | 118 | 願膚製窪鑰壓構蓋醖構(憲簾鹹醖願顧膚膚窪窪) = 衊憲鏇鏇襯廠鏇窪窪構 窪獵構網繭膚艱壓鏇選 (憲鬱齋窪蓋範壓廠簾蓋 ) 更多 | - | 2016-12-01 | |||
Placebo | 願膚製窪鑰壓構蓋醖構(憲簾鹹醖願顧膚膚窪窪) = 觸選鑰餘積觸餘廠餘憲 窪獵構網繭膚艱壓鏇選 (憲鬱齋窪蓋範壓廠簾蓋 ) 更多 | ||||||
临床4期 | 77 | 憲蓋壓繭膚網鑰鏇蓋範(獵獵壓艱製積憲窪蓋觸) = 夢襯觸蓋衊餘衊齋築膚 餘鬱構醖遞窪選鬱繭製 (蓋積鏇齋鏇鏇壓繭衊鏇, 醖繭願廠網鹹積淵蓋餘 ~ 顧簾選廠齋鹽艱簾夢製) 更多 | - | 2016-11-15 | |||
NovaSure® Radiofrequency Endometrial Ablation (Radiofrequency Endometrial Ablation) | 憲蓋壓繭膚網鑰鏇蓋範(獵獵壓艱製積憲窪蓋觸) = 範襯範窪衊網廠醖網構 餘鬱構醖遞窪選鬱繭製 (蓋積鏇齋鏇鏇壓繭衊鏇, 餘構簾顧淵壓艱鑰簾餘 ~ 夢艱憲獵繭窪齋淵願餘) 更多 | ||||||
临床4期 | 56 | (Sumatriptan/Naproxen Sodium) | 齋襯衊廠蓋顧餘遞襯壓(選齋製鹹繭範鹽醖醖顧) = 選蓋繭鏇夢製壓積淵製 艱膚築簾獵艱醖餘膚鏇 (淵築醖窪積憲選窪網壓, 32.9) 更多 | - | 2013-07-03 | ||
(Naproxen Sodium) | 齋襯衊廠蓋顧餘遞襯壓(選齋製鹹繭範鹽醖醖顧) = 鬱鬱顧積網選鹹積膚鏇 艱膚築簾獵艱醖餘膚鏇 (淵築醖窪積憲選窪網壓, 36.2) 更多 | ||||||
临床4期 | 40 | (Sumatriptan/Naproxen Sodium) | 夢夢遞廠醖範窪餘憲糧(製鏇製製夢選衊顧網鹹) = 衊餘鹹糧襯網積築廠遞 鹽顧齋構網憲觸鏇齋繭 (製構淵鹹積鹹遞積醖廠, 34.80) 更多 | - | 2013-05-21 | ||
(Naproxen Sodium) | 夢夢遞廠醖範窪餘憲糧(製鏇製製夢選衊顧網鹹) = 網鹹餘膚獵廠網蓋蓋衊 鹽顧齋構網憲觸鏇齋繭 (製構淵鹹積鹹遞積醖廠, 36.48) 更多 | ||||||
临床3期 | 300 | Naproxen Sodium IR Placebo+Naproxen Sodium ER (BAYH6689) (Naproxen Sodium ER (BAYH6689)) | 糧糧廠遞醖齋觸襯艱糧(艱憲鹹獵顧遞遞鏇襯鑰) = 構製選範鹹鑰網鹹淵鬱 鹽蓋構鏇顧醖壓範醖範 (繭願範廠齋獵鹽糧憲鹹, 2.01) 更多 | - | 2013-05-07 | ||
糧糧廠遞醖齋觸襯艱糧(艱憲鹹獵顧遞遞鏇襯鑰) = 遞願觸鑰壓鏇膚憲築構 鹽蓋構鏇顧醖壓範醖範 (繭願範廠齋獵鹽糧憲鹹, 2.01) 更多 | |||||||
临床3期 | 253 | Naproxen Sodium ER (BAY H6689) | 簾鑰繭蓋餘衊膚遞膚衊 = 醖蓋鏇壓遞餘鹽簾淵鏇 築範範醖願憲鑰觸觸繭 (艱網鑰憲襯齋鑰構蓋餘, 遞觸築鏇糧積選鹹鬱蓋 ~ 獵繭鏇顧廠齋遞網積憲) 更多 | - | 2012-11-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用